Patents by Inventor Marcel van den Brink
Marcel van den Brink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091265Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.Type: ApplicationFiled: June 12, 2023Publication date: March 21, 2024Applicants: Fred Hutchinson Cancer Center, Memorial Sloan-Kettering Cancer CenterInventors: Jarrod Dudakov, Marcel van den Brink, Enrico Velardi, Hans-Peter Kiem, Stefan Radtke, Scott James
-
Patent number: 11860163Abstract: The present invention relates to compositions, methods, and kits for predicting a subject's response to a CAR T cell therapy, by analyzing the intestinal microbiome of the subject. The present disclosure also provides a method of detecting patients at risk for a poor response to CAR T cell therapy by measuring the level of the presently disclosed bacteria or bacterial genes in the microflora or microbiome of a patient receiving or considered for CAR T cell therapy. The present disclosure further provides therapeutic compositions and methods for treating a subject having a cancer, by improving the subject's response to a CAR T cell therapy.Type: GrantFiled: April 13, 2021Date of Patent: January 2, 2024Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Melody Smith, Marcel van den Brink, Eric Pamer, Eric Littmann
-
Publication number: 20230416834Abstract: The present invention relates to methods and compositions for reducing the risk of cancer relapse in a subject who has received cancer treatment. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Streptococcus anginosus, Parvimonas micra, Acidaminococcus intestini, Eubacterium limosum, Clostridium glycyrrhizinilyticum, Desulfosporosinus lacus, Eubacterium biforme, Anaerofustis stercorihominis, Pseudoramibacter alactolyticus, Peptococcus niger, Armatimonas rosea, Saccharofermentans acetigenes, Finegoldia magna, Levyella massiliensis, Gallicola barnesae, Murdochiella asaccharolytica, and Eubacterium brachy are associated with a reduced risk of cancer relapse.Type: ApplicationFiled: March 6, 2023Publication date: December 28, 2023Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Marcel Van Den Brink, Robert Jenq, Jonathan U. Peled
-
Patent number: 11786557Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.Type: GrantFiled: October 2, 2018Date of Patent: October 17, 2023Assignee: Fred Hutchinson Cancer CenterInventors: Jarrod Dudakov, Marcel van den Brink, Enrico Velardi, Hans-Peter Kiem, Stefan Radtke, Scott James
-
Publication number: 20230293635Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.Type: ApplicationFiled: January 18, 2023Publication date: September 21, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, EVIVE BIOTECHNOLOGY (SHANGHAI) LTDInventors: Marcel VAN DEN BRINK, Alan HANASH, Caroline LINDEMANS, Tom TANG
-
Patent number: 11597979Abstract: The present invention relates to methods and compositions for reducing the risk of cancer relapse in a subject who has received cancer treatment. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Streptococcus anginosus, Parvimonas micra, Acidaminococcus intestini, Eubacterium limosum, Clostridium glycyrrhizinilyticum, Desulfosporosinus lacus, Eubacterium biforme, Anaerofustis stercorihominis, Pseudoramibacter alactolyticus, Peptococcus niger, Armatimonas rosea, Saccharofermentans acetigenes, Finegoldia magna, Levyella massiliensis, Gallicola barnesae, Murdochiella asaccharolytica, and Eubacterium brachy are associated with a reduced risk of cancer relapse.Type: GrantFiled: September 2, 2016Date of Patent: March 7, 2023Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Marcel Van Den Brink, Robert Jenq, Jonathan U. Peled
-
Patent number: 11564973Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.Type: GrantFiled: December 23, 2019Date of Patent: January 31, 2023Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EVIVE BIOTECHNOLOGY (SHANGHAI) LTDInventors: Marcel Van Den Brink, Alan Hanash, Caroline Lindemans, Tom Tang
-
Publication number: 20210231657Abstract: The present invention relates to compositions, methods, and kits for predicting a subject's response to a CAR T cell therapy, by analyzing the intestinal microbiome of the subject. The present disclosure also provides a method of detecting patients at risk for a poor response to CAR T cell therapy by measuring the level of the presently disclosed bacteria or bacterial genes in the microflora or microbiome of a patient receiving or considered for CAR T cell therapy. The present disclosure further provides therapeutic compositions and methods for treating a subject having a cancer, by improving the subject's response to a CAR T cell therapy.Type: ApplicationFiled: April 13, 2021Publication date: July 29, 2021Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Melody Smith, Marcel van den Brink, Eric Pamer, Eric Littmann
-
Publication number: 20210138038Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.Type: ApplicationFiled: December 23, 2019Publication date: May 13, 2021Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, GENERON (SHANGHAI) CORPORATION, LTD.Inventors: Marcel VAN DEN BRINK, Alan HANASH, Caroline LINDEMANS, Tom TANG
-
Publication number: 20200237827Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.Type: ApplicationFiled: October 2, 2018Publication date: July 30, 2020Applicants: Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer CenterInventors: Jarrod Dudakov, Marcel van den Brink, Enrico Velardi, Hans-Peter Kiem, Stefan Radtke, Scott James
-
Patent number: 10619134Abstract: The present disclosure describes methods to promote thymic regeneration following injury or damage to the thymus by administering to the thymus an effective amount of (1) bone morphogenetic protein 4 (BMP4), (2) thymus-derived endothelial cells that express BMP4 or (3) a combination of BMP4 and BMP4-secreting thymus-derived endothelial cells.Type: GrantFiled: April 27, 2017Date of Patent: April 14, 2020Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Jarrod Dudakov, Marcel Van Den Brink, Tobias Wertheimer
-
Publication number: 20200108091Abstract: Disclosed herein are methods for inhibiting irradiation- and chemo-induced impact on intestinal barrier function and graft versus host disease following allogeneic hematopoietic stem cell transplantation by targeting the RIG-I or STING signaling pathways.Type: ApplicationFiled: April 17, 2018Publication date: April 9, 2020Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHENInventors: Marcel VAN DEN BRINK, Hendrik POECK
-
Patent number: 10279011Abstract: The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination.Type: GrantFiled: June 15, 2015Date of Patent: May 7, 2019Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Jarrod Dudakov, Marcel van den Brink, Alan Hanash
-
Publication number: 20180274036Abstract: The present invention relates to methods and compositions for reducing the risk of cancer relapse in a subject who has received cancer treatment. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Streptococcus anginosus, Parvimonas micra, Acidaminococcus intestini, Eubacterium limosum, Clostridium glycyrrhizinilyticum, Desulfosporosinus lacus, Eubacterium biforme, Anaerofustis stercorihominis, Pseudoramibacter alactolyticus, Peptococcus niger, Armatimonas rosea, Saccharofermentans acetigenes, Finegoldia magna, Levyella massiliensis, Gallicola barnesae, Murdochiella asaccharolytica, and Eubacterium brachy are associated with a reduced risk of cancer relapse.Type: ApplicationFiled: September 2, 2016Publication date: September 27, 2018Inventors: Marcel Van Den Brink, Robert Jenq, Jonathan U. Peled
-
Publication number: 20170292111Abstract: The present disclosure describes methods to promote thymic regeneration following injury or damage to the thymus by administering to the thymus an effective amount of (1) bone morphogenetic protein 4 (BMP4), (2) thymus-derived endothelial cells that express BMP4 or (3) a combination of BMP4 and BMP4-secreting thymus-derived endothelial cells.Type: ApplicationFiled: April 27, 2017Publication date: October 12, 2017Inventors: Jarrod DUDAKOV, Marcel VAN DEN BRINK, Tobias WERTHEIMER
-
Publication number: 20170258854Abstract: The present disclosure describes compositions and methods for increasing the abundance of commensal bacteria belonging to the order Clostridiales, including Blautia, Ruminococcus, Clostridium, Eubacterium, Holdemania and Dorea species, that are associated with reduced lethal GVHD and improved overall survival following bone marrow or hematopoietic stem cell transplant. The present disclosure, therefore, provides methods for reducing the likelihood, incidence or severity of GVHD by (1) avoiding the loss of endogenous beneficial species through antibiotic selection; (2) by administering a therapeutically effective amount of a composition comprising one or more Clostridiales associated with reduced GVHD to individuals who may lack or have lost those strains from their intestinal microbiota.Type: ApplicationFiled: May 24, 2017Publication date: September 14, 2017Inventors: Marcel Van Den Brink, Robert Jenq, Eric G. Pamer, Ying Taur, Yusuke Shono
-
Publication number: 20160287670Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.Type: ApplicationFiled: November 7, 2014Publication date: October 6, 2016Inventors: Marcel VAN DEN BRINK, Alan HANASH, Caroline LINDEMANS, Tom TANG
-
Publication number: 20160136244Abstract: The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination.Type: ApplicationFiled: June 15, 2015Publication date: May 19, 2016Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Jarrod DUDAKOV, Marcel van den BRINK, Alan HANASH
-
Patent number: 9119824Abstract: The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination.Type: GrantFiled: May 17, 2012Date of Patent: September 1, 2015Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Jarrod Dudakov, Marcel van den Brink, Alan Hanash
-
Publication number: 20140248235Abstract: The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination.Type: ApplicationFiled: May 17, 2012Publication date: September 4, 2014Inventors: Jarrod Dudakov, Marcel van den Brink, Alan Hanash